Risk factor
Very high price volatility
Profitability factor
Very low or no dividends
About
Meribank Biotech Co., Ltd, established in 2013 and headquartered in Taipei City, Taiwan, is a company dedicated to the cultivation, advancement, and banking of mesenchymal stem cells. The firm specializes in the preservation of various cell types, including mesenchymal stem cells sourced from the placenta and umbilical cord, hematopoietic stem cells from cord blood, and diverse immune cells. Additionally, Meribank is involved in developing advanced cellular cryopreservation protocols and provides postpartum nursing services.
Company Valuation
From both historical and forecast perspectives, the stock is fairly priced compared to similar stocks. Specifically, the stock is overvalued on EV/EBITDA, reasonably pric